Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Baron Focused Growth Fund Q2 2026 Portfolio Update

Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.

Seeking Alpha • Sep 3, 2026

Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 31, 2026

IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.

Business Wire • Aug 31, 2026

Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 24, 2026

Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?

IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

Zacks Investment Research • Aug 21, 2026

IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

Zacks Investment Research • Aug 20, 2026

Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

Zacks Investment Research • Aug 19, 2026

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript

Seeking Alpha • Aug 18, 2026

IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests

IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.

MarketBeat • Aug 14, 2026